United Therapeutics wins on appeal against Sandoz's US antitrust claims over Remodulin
( October 7, 2026, 15:00 GMT | Official Statement) -- MLex Summary: United Therapeutics has sufficiently shown procompetitive justifications for its acquisition of all commercially available cartridges required for administering treprostinil under the skin through a wearable pump, according to a US appeals court. The US Court of Appeals for the Third Circuit affirmed the dismissal of Sandoz’s antitrust claims accusing UTC of illegally obstructing the release of a generic competitor to the drug Remodulin. “[T]he record shows that UTC’s procompetitive justifications are sincere, as UTC was consistently concerned about securing a cartridge supply for its own product. There is nothing pretextual about seeking to protect a procompetitive investment and also seizing the opportunity to disadvantage a competitor along the way,” US Circuit Judge L. Felipe Restrepo wrote in the opinion.See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.